Remove 2030 Remove Clinical Research Remove Regulations
article thumbnail

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research

Vial

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. What is a Pre-Clinical CRO? between 2024 and 2030. over this period.

article thumbnail

Six Factors for Biotech Companies to Consider When Choosing Next-Generation Contract GMP/CMC Laboratories

PPD

Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030. There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Evolution of Digital Patient Portals: Enhancing Healthcare Access and Engagement

Vial

In 2022, the global market value of patient portals within the clinical research and healthcare industries was estimated to be US $2.9 billion and is expected to climb at a compound annual growth rate (CAGR) of 19.44% between 2023 and 2030.

article thumbnail

Why Do Pharma Companies Outsource to CROs?

Vial

According to the 2022 Polaris Market Research Report , the global clinical trials outsourcing market reached USD 38.11 over the forecast period (2022-2030). This article discusses current challenges in managing clinical trials and elucidates the pivotal role that CROs play in overcoming these obstacles.

article thumbnail

7 Most Common Types of Depression

Olympian Clinical Research

Major depressive disorder ( MDD ), also known as clinical depression, is characterized by a persistent feeling of sadness or emptiness lasting for at least two weeks. According to the World Health Organization, major depressive disorder is projected to rank first as the top burden of disease worldwide by 2030.